Login or sign up
For business

Gemopharm LLC

4.0Β· 12 reviews
Average ratingGreat
4.0/ 5

Based on 12 reviews

533%
433%
333%
20%
10%
Ask AI

Ask Trustburn about Gemopharm LLC

Based on 12 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Gemopharm LLC

The lead asset is the monoclonal antibody based on a proprietary therapeutic platform to target CD71 selectively in the tumor microenvironment. Gemopharm’s approach mitigates potential toxicities that may occur from solicitation of non-selective complement dependent cytotoxicity (CDC) activation or addition of a toxin payload. Gemopharm has generated in vivo proof-of-concept data demonstrating substantial efficacy and validating the mechanism of action of the lead candidate. The pilot toxicology has been completed without any signs of toxicity (no mortalities, clinical signs, or DLTs observed). Gemopharm envisages that its lead candidate can address a high unmet need for effective therapies for relapsed/refractory primary and secondary central nervous system (CNS) and intraocular lymphomas (IOL).